Zura Bio Limited · NASDAQ:ZURA

Zura Bio — Investor Presentation (October 2023)

34 slides from Zura Bio's investor presentation, Oct 25, 2023

  1. Slide 1: Corporate Overview: Building the Next Immunology Leader

    ©2023 Zura Bio Ltd. Corporate Overview Last Updated: October 2023 Building the Next Immunology Leader

  2. Slide 2: Forward Looking Statements Disclaimer

    ©2023 Zura Bio Ltd. 2 Forward Looking Statements Disclaimer This communication includes “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “ant

  3. Slide 3: Experienced management team with proven ability to execute

    ©2023 Zura Bio Ltd. 3 Experienced management team with proven ability to successfully execute and build a leading market position Nasdaq: ZURA Verender Badial Chief Financial Officer Someit Sidhu M.D. Chief Executive Officer and Director Chris Cabell M.D. Chief Medical Officer and Head of Research a

  4. Slide 4: Sizeable Total Addressable Market Across Validated Mechanisms

    ©2023 Zura Bio Ltd. Sizeable Total Addressable Market Exists Across Number of Validated Mechanisms 4 Nasdaq: ZURA Room for growth across our three indications Approximately $4 Billion in growth anticipated by 2029 Sources: 1 Based on current annual gross price of marketed products 2 Based on 2023 gr

  5. Slide 5: Clinical stage pipeline targeting key immunology pathways

    ©2023 Zura Bio Ltd. Clinical stage pipeline targeting key immunology pathways 5 ZURA BIO PROGRAM INDICATION EXPECTED KEY MILESTONES Preclinical NEXT CLINICAL PHASE Phase 1 Phase 2 Phase 3 ZB - 106 tibulizumab Anti - BAFF x IL - 17 systemic sclerosis Transition asset from Eli - Lilly Open IND rheumat

  6. Slide 6: External Catalysts

    ©2023 Zura Bio Ltd. 6 ZB - 106 Program: External Catalyst ZB - 168 Program: External Catalyst ZB - 880 Program: External Catalyst L EG END: Sources: ClinicalTrial.gov, Company Press Release Abbreviations: AA, alopecia areata; AD, atopic dermatitis; COPD, chronic obstructive pulmonary disease; HS, hi

  7. Slide 7: Our Strategic Approach: Paradigm shift for patients

    ©2023 Zura Bio Ltd. Paradigm shift for patients Our approach could signify a paradigm shift for patients suffering from severe and intricate autoimmune diseases. These patients currently find their needs unmet by the conventional "single” pathway approach. Pioneering dual pathway biology Integrating

  8. Slide 8: Paradigm shifting not incrementalism

    ©2023 Zura Bio Ltd. Paradigm shifting not incrementalism 8 Nasdaq: ZURA PATIENTS NEED A PARADIGM SHIFT Hidradenitis suppurativa • IL - 17 treatments seem to have reached their efficacy ceiling • Overall disease burden still exists • Persistent inflammatory burden remains with a B - cell driven compo

  9. Slide 9: Pioneering Dual Pathway Biology

    ©2023 Zura Bio Ltd. Pioneering Dual Pathway Biology 9 Sources: 1 Liu, Ling, et al. Journal of Inflammation Research, doi:10.2147/jir.s100940. 2 Manetta, Joseph et al. Journal of Inflammation Research, doi:10.2147/jir.s67751. 3 Benschop, Robert J., et al. mAbs, doi:10.1080/19420862.2019.1624463. (*)

  10. Slide 10: Potent molecules with highly validated pathways

    TALTZ® Anti - IL - 17 scFv Anti - BAFF Ab t a ba l u m a b IL - 17 tibulizumab: BAFF / IL - 17 BAFF ZB - 168: IL - 7R / TSLP torudokimab: IL - 33 / RAGE Potent molecules with highly validated pathways Nasdaq: ZURA DOSING TO DATE 2 o 78 Participants Dosed Across Three Ph1/1b studies 57 participants w

  11. Slide 11: ZB-106 is Clinically De-Risked Through Ph1b

    ©2023 Zura Bio Ltd. ZB - 106 is Clinically De - Risked Through Ph1b 11 ▪ SAD Studies: No deaths or SAEs ▪ MAD study: No deaths, single related SAE of neutropenia with resolution ▪ Most frequent TEAE: Headache, transient neutropenia, nausea, diarrhea ▪ No TEAE of infection at target doses ▪ In the MA

  12. Slide 12: Combining IL-17 and BAFF Neutralization in a Murine Model of Arthritis

    ©2023 Zura Bio Ltd. Combining IL - 17 and BAFF Neutralization in a Murine Model of Arthritis Enables Improvement in Therapeutic Benefit 12 ▪ Rheumatoid arthritis is a prototypic autoimmune disease where individually targeting IL - 17 - mediated inflammation or depleting B cells has been clinically v

  13. Slide 13: ZB-106 tibulizumab: systemic sclerosis

    ©2023 Zura Bio Ltd. Potential First - in - Class, Dual Antagonist Combining tabalumab and TALTZ® ZB - 1 0 6 tibulizumab Anti - BAFF x IL - 17 systemic sclerosis (SSc)

  14. Slide 14: Systemic sclerosis is a rare & life-threatening disease

    ©2023 Zura Bio Ltd. zz zz zz zz 14 Systemic sclerosis is a rare & life - threatening disease with no approved therapy ~200,000 people with SSc in US, EU and Japan 1 40 - 60% mortality in 10 years 2 Zero SSc - specific * drugs approved $2B+ annual potential market opportunity Rare and life - threaten

  15. Slide 15: IL-17 and BAFF Inhibition Have Shown Efficacy in SSc

    ©2023 Zura Bio Ltd. IL - 17 efficacy in SSc Role of BAFF in SSc IL - 17 and BAFF Inhibition Have Shown Efficacy in Placebo Controlled Trials in systemic sclerosis (SSc) 15 S t rom al cells T1 - IFN BAF F P l a sm a cell C XC R5 + T fh cell T LS GC B cell C XC L1 3 • Brodalumab treatment in SSc leads

  16. Slide 16: Rituximab and Belimumab data in SSc

    ©2023 Zura Bio Ltd. 16 Rituximab CD20 B - cell depleter ▪ Multiple Studies demonstrated effectiveness of rituximab in SSc (mainly open label and observational) ▪ The most compelling data comes from the DESIRES double blind – placebo - controlled trial in 56 pts with SSc ▪ Primary endpoint: mRSS chan

  17. Slide 17: Phase 2 SSc Trial Design

    ©2023 Zura Bio Ltd. Phase 2 SSc Trial Design* 17 ZB - 106 | SSc KEY SAFETY ENDPOINTS KEY EFFICACY ENDPOINTS DOUBLE BLIND, PLACEBO - CONTROLLED TRIAL EFFICACY PERIOD (24 / 52 WEEKS) P L A C E B O ZB - 106 DOSE LEVEL 2 ZB - 106 DOSE LEVEL 1 R • FVC, DLCO • ACR - CRISS • Change in mRSS • SHAQ DI • VAS

  18. Slide 18: ZB-106 tibulizumab: hidradenitis suppurativa

    ©2023 Zura Bio Ltd. Potential First - in - Class, Dual Antagonist Combining tabalumab and TALTZ® ZB - 1 0 6 tibulizumab Anti - BAFF x IL - 17 hidradenitis suppurativa (HS)

  19. Slide 19: Overview of hidradenitis suppurativa (HS)

    ©2023 Zura Bio Ltd. Overview of hidradenitis suppurativa (HS) 19 Estimated ~300K people living with Hidradenitis suppurativa in the U.S. (1 - 2% global prevalence) Average of 7 years to diagnose globally High unmet need >50% patients still left inadequately treated According to HiSCR 75 data CURRENT

  20. Slide 20: Recent HS Data

    ©2023 Zura Bio Ltd. 20 RECENT HS DATA C om p a n y Asset h umir a cosentyx bimzelx bimzelx sonelokimab sonelokimab i z o k ib e p i z o k ib e p fo s t a m a t i n i b M ec Admi P Do Total Efficacy ( H i SCR 5 0 ) Efficacy ( H i S C R75) Safety / T o lera b ili t y hanism TNF - α IL - 17 A IL - 17 A

  21. Slide 21: B Cell Signaling Potentiates HS Disease

    ©2023 Zura Bio Ltd. B Cell Signaling Potentiates HS Disease 21 ZB - 106 | HS Sources: 1 Van der Zee, H.H., et al. British Journal of Dermatology, doi:10.1111/j.1365 - 2133.2011.10698. 2 Rumberger et al. 2020. J Inflam Research; 3 Sabat, Robert, et al. Journal of Allergy and Clinical Immunology, doi:

  22. Slide 22: Dermal Tunnels: Role in HS Pathogenesis

    ©2023 Zura Bio Ltd. Dermal Tunnels: Role in HS Pathogenesis 22 Sources: 1 Frew et al. 2021 Clin Exper Derm; 2 Sabat et al JACI 2023; 3 Moran et al. JID 2017; 4 Gudjonsson et al. 2020; 5 Jepsen et al. 2023. JAAD Treatment with fostamatinib (SYK Inhibitor) significantly reduced IHS4 scores and drainin

  23. Slide 23: Phase 2 HS Trial Design

    ©2023 Zura Bio Ltd. Phase 2 HS Trial Design* 23 ZB - 106 | HS KEY SAFETY ENDPOINTS KEY EFFICACY ENDPOINTS EFFICACY PERIOD (12 / 24 WEEKS) P L A C E B O ZB - 106 DOSE LEVEL 2 ZB - 106 DOSE LEVEL 1 Moderate to Severe HS Total abscess and inflammatory count (AN) ≥ 5 KEY INCLUSION CRITERIA DOUBLE BLIND,

  24. Slide 24: ZB-168 Anti-IL-7R: alopecia areata

    ©2023 Zura Bio Ltd. A Potential Best - in - Class Anti - IL - 7R Inhibiting Both IL - 7 and TSLP Pathways ZB - 1 6 8 Anti - IL - 7R alopecia areata (AA)

  25. Slide 25: Cytokine Signaling via IL-7 and TSLP Pathways

    ©2023 Zura Bio Ltd. 25 Cytokine Signaling via IL - 7 and TSLP Pathways ZB - 168 | AA IL - 7R α is a key receptor in immune regulation, central to the signaling of cytokines IL - 7 and TSLP Positioning ZB - 168 for diverse immune - related and autoimmune conditions Commonly tied to allergic responses

  26. Slide 26: Potential Therapeutic Franchises for ZB-168

    ©2023 Zura Bio Ltd. 26 Potential Therapeutic Franchises for ZB - 168 ZB - 168 | AA Sources: 1 ClinicalTrials.gov database Explore the potential indication space Solid biologic rationale for IL - 7 / TSLP E x p ec t ed Clinical Readout 1 Alopecia areata (and other Dermatology) Ulcerative colitis (and

  27. Slide 27: Redefining Treatment Standards for alopecia areata

    ©2023 Zura Bio Ltd. 27 Redefining Treatment Standards for alopecia areata ZB - 168 | AA Alopecia areata H i g h CD8 T effector memory CD4 T reg ZB - 16 8 I L - 7 R α L ow I L - 7 R α Universalis T o t a l is A r eat a Z B - 1 68 1, 2 Targets the T effector memory Preserves the T r eg Autoimmune dise

  28. Slide 28: ZB-168 is Potentially Best-in-Class at TSLP Inhibition

    ©2023 Zura Bio Ltd. 28 Anti - TSLPR t e z e p e l u m a b IgG ZB - 168 1 00 50 0 - 50 4 2 - 2 - 4 %Inhibition 0 Log (nm) % inhibition of TSLP stimulated CCL17 secretion from human monocytes ZB - 168 is Potentially Best - in - Class Asset at TSLP Inhibition ZB - 168 | AA ▪ ZB - 168 is nearly 10 - fol

  29. Slide 29: Current treatments involving JAK inhibitors

    ©2023 Zura Bio Ltd. 29 Current treatments involving JAK inhibitors ZB - 168 | AA JAK inhibitors block multiple pathways by targeting JAK1 and JAK2, which are involved in numerous cytokine signaling processes. This broad action will/can inadvertently suppress beneficial immune responses. Concerns wit

  30. Slide 30: Phase 2 AA Trial Design

    ©2023 Zura Bio Ltd. Phase 2 AA Trial Design* 30 (*) Trial design is subject to change due to factors such as regulatory feedback KEY SAFETY ENDPOINTS • General Safety and Tolerability • Severe infection • Neutropenia • ADA / nAb ZB - 168 | AA KEY EFFICACY ENDPOINTS • Percent change in SALT score • C

  31. Slide 31: ZB-880 torudokimab: Anti-IL-33

    ©2023 Zura Bio Ltd. Targeting Anti - IL - 33, an Alarmin with Potential in Multiple Indications ZB - 880 t or u do k i m a b Anti - IL - 33 allergy / respiratory Indications

  32. Slide 32: ZB-880 Asset Overview and Mechanism of Action

    ©2023 Zura Bio Ltd. Mechanism of Action About ZB - 880 (torudokimab) Initial Focus on Respiratory, Dermatologic, Gastrointestinal and Orphan Autoimmune Indications ZB - 880 Asset Overview 32 Sources: 1. Cohen et al. 2015 Nature, 2. https://clinicaltrials.gov/ct2/show/NCT03913260; https://clinicaltri

  33. Slide 33: ZB-880 IL-33 Pathway

    ©2023 Zura Bio Ltd. ZB - 880 IL - 33 Pathway 33 Sources: 1. Chan, 2019. Frontiers Immunol, 2. doi.org/10.1016/j.cyto.2022.155891, 3. https://doi.org/10.1038/ng.323 and doi:10.1016/j.jaci.2020.04.051 , 4. .:https://doi.org/10.1016/S2213 - 2600(22)00005 - 4; doi:10.1056/NEJMoa2024257 and doi: 10.1126/

  34. Slide 34: ZB-880 Has Potential for Best-in-Class Activity

    ©2023 Zura Bio Ltd. ZB - 880 Has Potential for “Best - in - Class” Activity 34 Torudokimab was 2.9 and 5.5 - fold more potent than etokimab and itepekimab , respectively, inhibiting IL - 33 - induced GM - CSF production by human mast cells Sources: Zura Bio Internal data Antibody k on (M - 1 s - 1 )

Zura Bio — Investor Presentation (October 2023) on 6ix